← FDA DRUG APPROVALS

FDA ANDA · ANDA211890

IBUPROFEN AND FAMOTIDINE

Sponsor: ALKEM LABS LTD

APPLICATION
ANDA211890
TYPE
ANDA
ORIGINAL APPROVAL
2021-08-03
LATEST ACTION
2026-07-16
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

IBUPROFEN AND FAMOTIDINEPrescription
FAMOTIDINE 26.6MG, IBUPROFEN 800MG · TABLET · ORAL

Approval history

2026-07-16Labeling · Supplement 7 · standardAP
2024-11-21Labeling · Supplement 6 · standardAP
2021-08-03UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →